Skip to content
Peptigraph home

AOD-9604 and Tesamorelin Together: What Is Known

AOD-9604 and Tesamorelin taken together: what each one is, how each is regulated, and what is known about combining them.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureUpdated
HGH fragment analogNot FDA approved · research chemicalAOD-9604Fragment of human growth hormone studied only in animals; in rats, 19 days of oral treatment reduced body-weight gain by over 50%.[5]GLP-1 & metabolicGHRH analogFDA approved (Egrifta)TesamorelinFDA-approved GHRH analog (Egrifta) for excess abdominal fat in HIV-associated lipodystrophy; visceral fat fell 15.2% versus a 5.0% rise with placebo in a randomized trial.[14]Growth hormone
Interaction notes

Timing, interactions and safety

Evidence for the combination

No studies tested these together (PubMed search: 3 results, 2 Oct 2026).

AOD-9604 is not FDA approved, and we have no sourced data on combining it with Tesamorelin.
Each component

Side by side

Showing 12 of 13 fields where the two differ. PCAC vote, Jul 2026 are the same or both unknown.

FieldAOD-9604Tesamorelin
ClassHGH fragment analogGHRH analog
Also calledAODtesa, Egrifta
CategoryGLP-1 & metabolicGrowth hormone
FDA statusNot FDA approved · research chemicalFDA approved (Egrifta)
WADAProhibited by WADA (S2.2.3)AOD-9604 is named as a growth hormone fragment in S2.2.3, prohibited at all times.Prohibited by WADA (S2.2.4)Tesamorelin is named as a GHRH analogue in S2.2.4 (growth hormone releasing factors), prohibited at all times. Tesamorelin is also an FDA-approved medicine; an athlete would need a therapeutic use exemption.
Anti-doping detection
  • AOD9604 can be detected in urine at 50 pg/mL; a stable serum metabolite may lengthen the detection window.PMID 25208511
  • Screening for a stable metabolite may allow a longer detection window (no duration was given).PMID 25208511
  • A urine assay detects CJC-1295 and other GHRH analogues at very low concentrations.PMID 35298973
  • Labs expect GHRH analogues like CJC-1295 to be hard to find because of tiny urine concentrations; the study reports no detections in routine anti-doping samples.PMID 34665524
Half-lifeNo published half-life foundPubMed search, 11 Oct 202611 minutessubcutaneous (EGRIFTA WR 1.28 mg) · FDA label (Egrifta WR)
Evidence strengthAnimal evidence, 2 of 4Strongest: Annals of clinical and laboratory science 2015, PMID 26275694Human RCT evidence, 4 of 4Strongest: eNeurologicalSci 2026, PMID 42382101
Human studies we summarised0 human (0 randomized or controlled) of 4 summarised12 human (11 randomized or controlled) of 16 summarised
Typical study doses
Vial sizes sold2 mg, 5 mg, 10 mg2 mg, 5 mg, 10 mg, 20 mg
Named in FDA warning letters, 2026Not in the letters we trackYes (24 Aug 2026)
Related tools

AOD-9604 vs Tesamorelin

Choosing between the two rather than combining them? The comparison lines them up field by field.

Open the comparison

Human evidence on one side, animal evidence on the other

A meta-analysis found tesamorelin significantly reduced visceral adipose tissue.[16]

A tesamorelin trial secondary analysis found it increased skeletal muscle area and density in patients who lost visceral fat.[12]

In obese mice, AOD-9604 and hGH both reduced body-weight gain; unlike hGH, AOD9604 did not induce hyperglycaemia or reduce insulin secretion.[17]

An industry profile notes that by February 2002 phase IIa trials were underway.[18]

What FDA says

FDA's safety-risk note on AOD-9604 says it has identified serious adverse events that may be associated with it, though causality is unclear.[19]

Tesamorelin's label lists an increased risk of neoplasms among its warnings.[9]

WADA lists AOD-9604 under growth hormone fragments.[2]

A PubMed search on 2 Oct 2026 for AOD-9604 with tesamorelin matched 3 records; none is recorded as a trial giving both.

Calculated from pubmed query ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab]); records matched 3; search date 2026-10-02. Formula: records_matched = PubMed count recorded in combinations.json for the query on search_date

Common questions

Can you take AOD-9604 with tesamorelin?

No study in the cached results tested them together, and FDA reports serious adverse events that may be associated with AOD-9604.[19]

Is AOD-9604 approved for weight loss?

No. FDA's database search for AOD-9604 returned no approved products.[20]

Sources

  1. 1FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
  2. 2World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
  3. 3Detection and in vitro metabolism of AOD9604.Drug testing and analysis · 2015PMID 25208511Accessed 2 Oct 2026
  4. 4Effect of Intra-articular Injection of AOD9604 with or without Hyaluronic Acid in Rabbit Osteoarthritis Model.Annals of clinical and laboratory science · 2015PMID 26275694Accessed 2 Oct 2026
  5. 5Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone.Hormone research · 2000PMID 11146367Accessed 2 Oct 2026
  6. 6PubMed search: AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab] (22 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  7. 7An antibody-free, ultrafiltration-based assay for the detection of growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS.Journal of pharmaceutical and biomedical analysis · 2022PMID 35298973Accessed 2 Oct 2026
  8. 8Advances in the detection of growth hormone releasing hormone synthetic analogs.Drug testing and analysis · 2021PMID 34665524Accessed 2 Oct 2026
  9. 9EGRIFTA WR (TESAMORELIN) KIT [THERATECHNOLOGIES INC.]FDA label (Egrifta WR), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
  10. 10The effect of growth hormone-releasing hormone on cognition and brain connectivity in adults with cognition ranging from normal to mild cognitive impairment.eNeurologicalSci · 2026PMID 42382101Accessed 2 Oct 2026
  11. 11Effects of tesamorelin on non-alcoholic fatty liver disease in HIV: a randomised, double-blind, multicentre trial.The lancet. HIV · 2019PMID 31611038Accessed 2 Oct 2026
  12. 12The Growth Hormone Releasing Hormone Analogue, Tesamorelin, Decreases Muscle Fat and Increases Muscle Area in Adults with HIV.The Journal of frailty & aging · 2019PMID 31237318Accessed 2 Oct 2026
  13. 13PubMed search: ("AOD-9604"[tiab] OR AOD9604[tiab]) AND (tesamorelin[tiab] OR Egrifta[tiab] OR TH9507[tiab] OR "TH-9507"[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Metabolic effects of a growth hormone-releasing factor in patients with HIV.The New England journal of medicine · 2007PMID 18057338Accessed 2 Oct 2026
  15. 15PubMed search: (AOD9604[tiab] OR "AOD-9604"[tiab] OR "AOD 9604"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  16. 16Efficacy and Safety of Tesamorelin in People Living With HIV (PLWH) With Lipodystrophy: A Systematic Review and Meta-Analysis.Journal of the International Association of Providers of AIDS Care · 2026PMID 42538058Accessed 2 Oct 2026
  17. 17Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment.International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity · 2001PMID 11673763Accessed 2 Oct 2026
  18. 18AOD-9604 Metabolic.Current opinion in investigational drugs (London, England : 2000) · 2004PMID 15134286Accessed 2 Oct 2026
  19. 19Official web pageOfficial web page · web page
  20. 20Drugs@FDA (openFDA) search: active ingredient "AOD-9604"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.